UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2334-5
Program Prior Authorization/Medical Necessity
Medication Bimzelx® (bimekizumab-bkzx)
P&T Approval Date 4/2024, 6/2024, 10/2024, 1/2025, 4/2025
Effective Date 6/1/2025
1. Background:
Bimzelx (bimekizumab-bkzx) is a humanized interleukin-17A and F antagonist indicated for
the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic
therapy or phototherapy, adults with active psoriatic arthritis, adults with active non-
radiographic axial spondyloarthritis with objective signs of inflammation adults with active
ankylosing spondylitis, and adults with moderate to severe hidradenitis suppurativa.
2. Coverage Criteriaa:
A. Plaque Psoriasis (PsO)
1. Initial Authorization
a. Bimzelx will be approved based on the following criterion:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) One of the following:
(a) All of the following:
i. Greater than or equal to 3% body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
ii. History of failure to one of the following topical therapies, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trial):
• Corticosteroids (e.g., betamethasone, clobetasol, desonide)
• Vitamin D analogs (e.g., calcitriol, calcipotriene)
• Tazarotene
• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
• Anthralin
• Coal tar
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
iii. History of failure to a 3 month trial of methotrexate at the maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of plaque psoriasis as documented by claims
history or submission of medical records (document drug, date, and duration
of therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab,
Orencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq
(brodalumab), Ilumya (tildrakizumab), Otezla (apremilast)]
-AND-
(3) One of the following:
(a) History of failure, contraindication, or intolerance to two of the
following (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Skyrizi (risankizumab)
vi. Sotyktu (deucravacitinib)
vii. One of the preferred ustekinumab productsc
viii. Tremfya (guselkumab)
-OR-
(b) Both of the following:
i. Patient is currently on Bimzelx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a UCB sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
free supply of medication) as a means to establish as a current user of
Bimzelx*
-AND-
© 2025 UnitedHealthcare Services, Inc.
2
(4) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(5) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a UCB sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bimzelx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Bimzelx therapy
-AND-
(2) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Taltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Bimzelx will be approved based on the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) One of the following:
© 2025 UnitedHealthcare Services, Inc.
3
(a) History of failure to a 3 month trial of methotrexate at maximally indicated
dose, unless contraindicated or clinically significant adverse effects are
experienced (document date and duration of trial)b
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of psoriatic arthritis as documented by claims
history or submission of medical records (Document drug, date, and
duration of therapy) [e.g., Cimzia (certolizumab), Cosentyx (secukinumab),
adalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab),
Xeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi
(risankizumab), Rinvoq (upadacitinib), Enbrel (etanercept)]
-AND-
(3) One of the following:
(a) History of failure, contraindication, or intolerance to two of the following
preferred products (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Rinvoq (upadacitinib)
vi. Simponi (golimumab)
vii. Skyrizi (risankizumab)
viii. One of the preferred ustekinumab productsc
ix. Tremfya (guselkumab)
x. Xeljanz/Xeljanz XR (tofacitinib)
-OR-
(b) Both of the following:
i. Patient is currently on Bimzelx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a UCB sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
free supply of medication) as a means to establish as a current user of
Bimzelx*
-AND-
© 2025 UnitedHealthcare Services, Inc.
4
(4) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(5) Prescribed by or in consultation with one of the following:
(a) Rheumatologist
(b) Dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a UCB sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bimzelx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Bimzelx therapy
-AND-
(2) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
C. Ankylosing Spondylitis (AS)
1. Initial Authorization
a. Bimzelx will be approved based on the following criteria:
(1) Diagnosis of active ankylosing spondylitis
-AND-
(2) One of the following:
© 2025 UnitedHealthcare Services, Inc.
5
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at
maximally indicated doses, each used for at least 4 weeks, unless
contraindicated or clinically significant adverse effects are experienced
(document drug, date, and duration of trials)
-OR-
(b) Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of ankylosing spondylitis as documented
by claims history or submission of medical records (Document drug,
date, and duration of therapy) [e.g., adalimumab, Simponi (golimumab),
Rinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), Enbrel
(etanercept)].
-AND-
(3) One of the following:
(a) History of failure, contraindication, or intolerance to two of the following
preferred products (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Rinvoq (upadacitinib)
vi. Simponi (golimumab)
vii. Xeljanz/Xeljanz XR (tofacitinib)
-OR-
(b) Both of the following:
i. Patient is currently on Bimzelx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a UCB sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
free supply of medication) as a means to establish as a current user of
Bimzelx*
-AND-
(4) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx
© 2025 UnitedHealthcare Services, Inc.
6
(secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
-AND-
(5) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a UCB sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bimzelx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Bimzelx therapy
-AND-
(1) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
D. Non-radiographic Axial Spondyloarthritis
1. Initial Authorization
a. Bimzelx will be approved based on the following criteria:
(1) Diagnosis of active non-radiographic axial spondyloarthritis
-AND-
(2) One of the following:
(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
(b) Patient has been previously treated with a targeted immunomodulator FDA-
approved for the treatment of non-radiographic axial spondyloarthritis as
© 2025 UnitedHealthcare Services, Inc.
7
documented by claims history or submission of medical records (Document
drug, date, and duration of therapy) [e.g. Cimzia (certolizumab), Cosentyx
(secukinumab), Rinvoq (upadacitinib)].
-AND-
(3) One of the following:
(a) History of failure, contraindication, or intolerance to two of the following
preferred products (document drug, date, and duration of trial):
i. Cimzia (certolizumab)
ii. Cosentyx (secukinumab)
iii. Rinvoq (upadacitinib)
-OR-
(b) Both of the following:
i. Patient is currently on Bimzelx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a UCB sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
free supply of medication) as a means to establish as a current user of
Bimzelx*
-AND-
(4) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx
(secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab,
Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]
-AND-
(5) Prescribed by or in consultation with a rheumatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a UCB sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services, Inc.
8
a. Bimzelx will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Bimzelx therapy
-AND-
(1) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),
Orencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
E. Hidradenitis Suppurativa (HS)
1. Initial Authorization
a. Bimzelx will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage
II or III)
-AND-
(2) One of the following:
(a) Both of the following:
i. History of failure to at least one oral antibiotic (e.g., doxycycline,
clindamycin, rifampin) at maximally indicated doses, unless
contraindicated or clinically significant adverse effects are
experienced (document drug, date, and duration of trial)
-AND-
ii. History of failure, contraindication, or intolerance to both of the
following preferred products (document drug, date, and duration of
trial):
• One of the preferred adalimumab productsc
• Cosentyx (secukinumab)
-OR-
(b) Both of the following:
i. Patient is currently on Bimzelx therapy as documented by claims history
or submission of medical records (Document date and duration of
therapy):
© 2025 UnitedHealthcare Services, Inc.
9
-AND-
ii. Patient has not received a manufacturer supplied sample at no cost in the
prescriber’s office, or any form of assistance from a UCB sponsored
program (e.g., sample card which can be redeemed at a pharmacy for a
free supply of medication) as a means to establish as a current user of
Bimzelx*
-AND-
(3) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx
(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),
Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]
-AND-
(4) Prescribed by or in consultation with a dermatologist
* Patients requesting initial authorization who were established on therapy via the
receipt of a manufacturer supplied sample at no cost in the prescriber’s office or any
form of assistance from a UCB sponsored program shall be required to meet initial
authorization criteria as if patient were new to therapy.
Authorization will be issued for 12 months.
2. Reauthorization
a. Bimzelx will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Bimzelx therapy.
-AND-
(2) Patient is not receiving Bimzelx in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx
(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia
(abatacept), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
c For a list of preferred products please reference drug coverage tools.
© 2025 UnitedHealthcare Services, Inc.
10
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Bimzelx [package insert]. Smyrna, GA: UCB, Inc.; November 2024
2. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update
2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol
2015;29:2277-94.
3. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management
and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
Program Prior Authorization/Medical Necessity - Bimzelx (bimekizumab-bkzx)
Change Control
4/2024 New program
6/2024 Added requirement for medical record submission for all authorization
criteria. Updated trial/failure criteria for Cosentyx. Removed
reauthorization criteria.
10/2024 Updated step requirement noting Adalimumab-adaz (unbranded
Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab
products with no change to clinical intent. Removed preferred
adalimumab footnote. Added Sotyktu as step therapy agent for PsO.
Changed number of step requirement to two and added continutation of
care if already on Bimzelx. Removed notation of exclusion. Added
coverage criteria for PsA, AS, and nr-axSpA. Updated background and
reference.
1/2025 Added criteria for hidradenitis suppurativa. Updated background and
reference.
4/2025 Removed examples for adalimumab in step therapy. Changed Stelara
step therapy to “One of the preferred ustekinumab productsc”. Changed
Stelara example to Ustekinumab. Added the footnote “For a list of
preferred products please reference drug coverage tools.”
© 2025 UnitedHealthcare Services, Inc.
11